English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The aim of the investigation was to study clinical efficacy and cardio safety of long-acting β2-agonist indacaterol in patients with chronic obstructive pulmonary disease (COPD) I–II grade in the stage of moderate exacerbation with concomitant ischemic heart disease. Material and Methods. Twenty patients (10 men and 10 women) with COPD and associated ischemic heart disease aged from 46 to 66 years (average age 57.2±7.9 years) have been examined. All patients received 150 μg/day of β2-agonist indacaterol for the treatment COPD during the entire period of observation. Prior to and 3 weeks after the treatment, a complex examination was carried out, including external respiratory function examination 6-minute walk test, and daily ECG monitoring. Results. By week 3 all patients noted decrease of the main respiratory symptoms. Forced expiratory volume in 1 s before the treatment was 57.64±9.67%, after it reached 64.72±5.45%. Physical load tolerance increased, which is confirmed by 6-minute walk test (initially 345.4±59.2 m, after the treatment 412.8±11.1 m). The results of repeated daily ECG monitoring (at week 3) did not show any new cases of arrhythmia or aggravation of myocardium ischemia. Conclusion. 150 μg/day of indacaterol in patients with I–II grade COPD in the stage of moderate exacerbation with concomitant cardiovascular pathology does not affect cardio safety.

Application of Long-Acting β2-Agonists in the Therapy of Chronic Obstructive Pulmonary Disease in Patients with Сonсomitant Ischemic Heart Disease